読み込み中
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
前日終値
$3.77
+$0.02 · +0.53%
日中の時刻はETです。市場データは遅延する場合があります。
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $3.77
52週レンジ
現在 $3.77
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
34
割高
センチメント
35
弱気
リスク
86
極めて高いリスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $3.77
52週レンジ
現在 $3.77
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 8000万 USD | 280.5万 USD | 634.2万 USD | 1916.3万 USD |
| 売上原価 | 139万 USD | 6338.6万 USD | 7180.1万 USD | 7678.2万 USD | 6970.1万 USD |
| 粗利益 | −139万 USD | 1661.4万 USD | −6899.6万 USD | −7044万 USD | −5053.8万 USD |
| 研究開発 | 5610.3万 USD | 6338.6万 USD | 7180.1万 USD | 7678.2万 USD | 6970.1万 USD |
| 販売・一般管理 | 2866.6万 USD | 3644.8万 USD | 4166.8万 USD | 4169.4万 USD | 3051.6万 USD |
| 営業費用 | 8337.9万 USD | 3851.1万 USD | 4166.8万 USD | 4212.1万 USD | 3051.6万 USD |
| 受取利息 | — | — | — | — | 20.7万 USD |
| 減価償却費と償却費 | 139万 USD | 159.3万 USD | 217.2万 USD | 241.4万 USD | 251.5万 USD |
| 営業利益 | −8476.9万 USD | −2189.7万 USD | −1.11億 USD | −1.13億 USD | −8105.4万 USD |
| 純利益 | −7488万 USD | −972.5万 USD | −9733.5万 USD | −1.1億 USD | −8084.7万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI806.92万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM666.86万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF215.26万0.00%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB214.63万0.02%108.2億 USD0.44%$206.49+3.00%
Fidelity Enhanced Small Cap ETFFESM191.43万0.03%64.1億 USD0.28%$45.46+0.46%
Vanguard Russell 2000 ETFVTWO132.27万0.01%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA122.95万0.01%218.24億 USD0.03%$32.79+0.40%
iShares Micro-Cap ETFIWC79.73万0.06%13.17億 USD0.60%$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
